Wake Network Developing Genetics-Based Screening System to Offer Patients Personalized Psychedelic Therapies

Wake Network Partners with Lieber Institute to Develop Genetics-Based Screening System for Psychedelic Therapies

, ,
Fungi bioscience company describes the project as “one of the most robust genetics research initiatives in the emerging psychedelics space to date."

Interview With Jemie Sae Koo

In this episode of the Psychedelic Spotlight podcast, we feature Jemie Sae Koo, CEO and Founder of Psychable.

The Spotlight Roundup-Can Psychedelics Help Brain Trauma?

July 21, 2021- This week’s Psychedelic Business News top stories include: - Wesana Health & The University of Southern Carolina Team up To Develop More Effective Treatments for TBI - The World's Largest Psychedelic Trial To Date Achieves…

Free Ketamine Treatment Now Available for Canadian Veterans

Medavie Blue Cross partners with medical research company Braxia Scientific to cover ketamine care for veterans at Canadian Rapid Treatment Centres of Excellence.
Levitee Labs joins Canadian Securities Exchange CSE

Levitee Labs to Begin Trading on the CSE This Week

The emerging wellness company aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.
'PSY' Becomes First U.S.-Listed Psychedelic ETF

Third Psychedelic Stock ETF Coming Soon, Core One Labs Prepares to List on NASDAQ

Advisorshares Plant Medicine ETF will be listed on the NYSE Arca under the symbol PSIL.
Traumatic Brain Injury (TBI) psychedelic treatment daniel carcillo

How Wesana Health CEO Daniel Carcillo Plans to Protect Athletes From Traumatic Brain Injury

,
And why the two-time Stanley Cup champion does not imagine working with the NHL in the "near future."
Psychedelic Business Spotlight, July 16

Psychedelic Business Spotlight: July 16, 2021

,
This week in psychedelic business news: A generous donation to advance MDMA research, psilocybin for end-of-life anxiety, and provisional patents filed for synthesizing ibogaine.
COVID-19 Pandemic Study of Ketamine Amplifies Antidepressant Potential

COVID-19 Pandemic Study of Ketamine Therapy Amplifies Antidepressant Potential

,
Study authors even believe "treating serious mental illness may reduce adverse outcomes related to COVID-19."

Global Trac Solutions Expands Investment in Psychedelic App PsycheDev and You Can Test It Out

The PsycheDev app guides users through intention setting, meditation, learning, contemplation and questioning, serving as a virtual facilitator and integration coach.